Adocia S.A. (ADOIF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Adocia S.A. (ADOIF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 52/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Adocia S.A. (ADOIF) Resumen de Asistencia Médica y Tuberías
Adocia S.A., a French clinical-stage biotech, leverages its BioChaperone platform to develop improved formulations of approved therapeutic proteins for diabetes and metabolic diseases. Their pipeline focuses on enhancing insulin therapies and exploring multi-hormonal treatments for obesity, positioning them in a competitive landscape of pharmaceutical innovation.
Tesis de Inversión
Adocia S.A. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's BioChaperone platform offers the potential to create differentiated insulin and multi-hormonal therapies. Key value drivers include the successful clinical development and commercialization of BioChaperone Lispro and BioChaperone Combo, particularly in partnership with Tonghua Dongbao. Upcoming clinical trial results for its lead candidates represent near-term catalysts. However, the company's negative profit and gross margins (-84.3% and -77.5% respectively) and reliance on partnerships introduce significant financial and operational risks. The company's market capitalization is approximately $0.10 billion, reflecting the speculative nature of its pipeline.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Adocia S.A. specializes in developing innovative formulations of therapeutic proteins and peptides for diabetes and metabolic diseases.
- The company's proprietary BioChaperone platform aims to enhance the efficacy and safety profiles of existing treatments.
- Adocia's clinical pipeline includes ultra-rapid insulin formulations (BioChaperone Lispro) and combination therapies (BioChaperone Combo).
- A strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. focuses on commercializing BioChaperone Lispro and Combo in China and other Asian and Middle Eastern territories.
- The company's preclinical pipeline explores bi-hormonal and multi-hormonal products for the treatment of obesity.
Competidores y Pares
Fortalezas
- Proprietary BioChaperone platform for enhanced drug delivery.
- Strategic partnership with Tonghua Dongbao for Asian markets.
- Diverse pipeline of insulin and multi-hormonal therapies.
- Focus on addressing unmet needs in diabetes and obesity treatment.
Debilidades
- Negative profit and gross margins.
- Reliance on partnerships for commercialization.
- Limited financial resources.
- High dependence on clinical trial success.
Catalizadores
- Upcoming: Clinical trial results for BioChaperone Lispro.
- Upcoming: Regulatory submissions for BioChaperone Combo.
- Ongoing: Expansion of strategic partnerships.
- Ongoing: Advancement of multi-hormonal obesity programs.
Riesgos
- Potential: Clinical trial failures.
- Potential: Regulatory hurdles.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources.
- Potential: Dependence on key partnerships.
Oportunidades de crecimiento
- BioChaperone Lispro Commercialization: Adocia's lead product, BioChaperone Lispro, represents a significant growth opportunity. This ultra-rapid insulin formulation aims to improve post-meal glucose control for diabetic patients. Successful clinical trials and subsequent commercialization, particularly in partnership with Tonghua Dongbao in China, could drive substantial revenue growth. The global market for insulin therapies is estimated to be several billion dollars annually, offering a large potential market for BioChaperone Lispro.
- BioChaperone Combo Development: The BioChaperone Combo, a combination of insulin glargine and rapid-acting insulin lispro, addresses the need for more convenient and effective diabetes management. Positive clinical trial results and regulatory approvals could position BioChaperone Combo as a competitive alternative to existing combination therapies. The market for combination diabetes drugs is growing, driven by the desire for simplified treatment regimens.
- Expansion of Strategic Partnerships: Adocia's strategic alliance with Tonghua Dongbao is crucial for its growth in the Asian market. Expanding partnerships with other pharmaceutical companies could provide access to new markets and funding for further development of its pipeline. Strategic collaborations can accelerate the commercialization of Adocia's products and reduce its financial risk.
- Advancement of Multi-Hormonal Obesity Programs: Adocia's preclinical pipeline includes multi-hormonal products for the treatment of obesity, such as BioChaperone GluExe and PramExe. These programs target multiple pathways involved in appetite regulation and energy expenditure. Successful preclinical and clinical development could lead to novel obesity therapies with significant market potential. The global obesity market is estimated to be worth billions of dollars, reflecting the growing prevalence of obesity worldwide.
- Lifecycle Management of Existing Products: As existing insulin therapies face increasing competition from biosimilars, Adocia's BioChaperone platform offers the potential to develop improved versions of these products. By enhancing the efficacy and safety profiles of established insulin formulations, Adocia can extend their market life and maintain revenue streams. Lifecycle management strategies are essential for pharmaceutical companies to sustain growth in a competitive market.
Oportunidades
- Expanding partnerships with other pharmaceutical companies.
- Successful clinical development of lead candidates.
- Growing demand for improved diabetes and obesity therapies.
- Potential for regulatory approvals in key markets.
Amenazas
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Regulatory hurdles.
- Biosimilar competition.
Ventajas competitivas
- Proprietary BioChaperone technological platform.
- Expertise in formulation development.
- Strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd.
- Pipeline of innovative insulin and multi-hormonal therapies.
Acerca de ADOIF
Adocia S.A., founded in 2005 and headquartered in Lyon, France, is a biotechnology company specializing in the research and development of innovative formulations of pre-approved therapeutic proteins and peptides. The company targets diabetes and other metabolic diseases, leveraging its proprietary BioChaperone technological platform. This platform is designed to optimize the performance of therapeutic proteins, aiming to improve their efficacy, safety, and patient convenience. Adocia's clinical product pipeline features insulin formulations like BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro. Other clinical-stage products include BioChaperone Combo, a combination of insulin glargine and rapid-acting insulin lispro, and BioChaperone LisPram, combining prandial insulin with pramlintide. The company is also developing BioChaperone Glucagon, an aqueous formulation of human glucagon for hypoglycemia treatment, and M1Pram, a metabolite of insulin glargine and pramlintide. Adocia's preclinical pipeline includes bi-hormonal and multi-hormonal products for obesity, such as BioChaperone GluExe, PramExe, and BioChaperone PramGluExe. Adocia has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories.
Qué hacen
- Researches and develops formulations of therapeutic proteins and peptides.
- Focuses on treatments for diabetes and other metabolic diseases.
- Utilizes its proprietary BioChaperone technological platform to optimize protein performance.
- Develops ultra-rapid insulin formulations.
- Creates combination therapies for diabetes management.
- Explores multi-hormonal products for obesity treatment.
Modelo de Negocio
- Develops proprietary formulations of existing therapeutic proteins and peptides.
- Out-licenses its products to pharmaceutical companies for commercialization.
- Generates revenue through upfront payments, milestone payments, and royalties on sales.
- Focuses on partnering with companies that have established distribution networks.
Contexto de la Industria
Adocia S.A. operates in the competitive biotechnology industry, specifically targeting the diabetes and obesity markets. The diabetes market is driven by the increasing prevalence of the disease globally, with a growing demand for improved insulin therapies. The obesity market is also expanding, fueled by lifestyle changes and a greater awareness of health risks. Adocia competes with established pharmaceutical companies and other biotech firms developing novel treatments for these conditions. Success depends on demonstrating superior efficacy, safety, and convenience compared to existing therapies.
Clientes Clave
- Pharmaceutical companies seeking to expand their diabetes and obesity portfolios.
- Patients with diabetes and other metabolic diseases.
- Healthcare providers who prescribe and administer Adocia's products.
- Tonghua Dongbao Pharmaceutical Co., Ltd. (strategic alliance partner).
Finanzas
Gráfico e información
Precio de la acción de Adocia S.A. (ADOIF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para ADOIF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ADOIF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ADOIF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ADOIF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Olivier Soula
Chief Executive Officer
Olivier Soula serves as the Chief Executive Officer of Adocia S.A. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held various leadership positions, contributing to strategic planning, business development, and product commercialization. Soula's expertise spans across multiple therapeutic areas, with a particular focus on metabolic diseases. His educational credentials and previous roles have equipped him with the skills necessary to lead Adocia through its clinical development programs and commercialization efforts.
Historial: Under Olivier Soula's leadership, Adocia S.A. has focused on advancing its clinical pipeline, particularly the BioChaperone Lispro and BioChaperone Combo programs. He has overseen the strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd., which is critical for the company's expansion in the Asian market. Soula has also guided the company through various financing rounds and corporate milestones.
Información del mercado OTC de ADOIF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Adocia S.A. (ADOIF) may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors and may be subject to less regulatory oversight than exchange-listed companies. Investing in OTC Other stocks carries significantly higher risks due to the potential for fraud, lack of liquidity, and limited transparency. Stocks on major exchanges like NYSE or NASDAQ must meet stringent listing requirements, including minimum share price, market capitalization, and financial reporting standards, offering greater investor protection.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume and liquidity can lead to price volatility.
- Potential for delisting or trading suspensions.
- Higher risk of fraud or manipulation compared to exchange-listed companies.
- OTC Other stocks are subject to less regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capitalization structure.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd.
- Focus on developing innovative therapies for diabetes and obesity.
- Proprietary BioChaperone technological platform.
- Clinical-stage product pipeline.
Lo Que los Inversores Preguntan Sobre Adocia S.A. (ADOIF)
¿Cuáles son los factores clave para evaluar ADOIF?
Adocia S.A. (ADOIF) actualmente tiene una puntuación IA de 52/100, indicando puntuación moderada. Fortaleza clave: Proprietary BioChaperone platform for enhanced drug delivery.. Riesgo principal a monitorear: Potential: Clinical trial failures.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ADOIF?
ADOIF actualmente puntúa 52/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ADOIF?
Los precios de ADOIF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ADOIF?
La cobertura de analistas para ADOIF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ADOIF?
Las categorías de riesgo para ADOIF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ADOIF?
La relación P/E para ADOIF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ADOIF sobrevalorada o infravalorada?
Determinar si Adocia S.A. (ADOIF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ADOIF?
Adocia S.A. (ADOIF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is based on available information and may be subject to change.
- OTC market data may have limited reliability.